Molecure – executive interview with Marcin Szumowski, CEO

Molecure – executive interview with Marcin Szumowski, CEO

Molecure — 2 videos in collection

More on this equity

Molecure is a clinical-stage biotechnology company focused on medicinal chemistry and biology capabilities to discover and develop first-in-class small molecule drug candidates that directly modulate the function of RNA and underexplored protein targets designed to treat multiple incurable diseases. Molecure is entering FY23 with two active clinical programmes. OATD-01, the company’s lead proprietary asset, is in development for the treatment of sarcoidosis, but management expects to expand into new indications if the data are supportive. Molecure also recently reported the first dosing in the Phase I trial for OATD-02, a novel drug for the treatment of solid tumours; an update for this study is expected in Q423.

In this video, Marcin Szumowski, Molecure’s CEO, provides background on the company’s developmental pipeline, highlighting the near-term priorities and plans.

You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free